Abstract

The pharmacological treatment of depression is often hampered by side-effects and unsatisfactory response to treatment.

Vortioxetine is one of the newest antidepressants on the market, purportedly with a different mechanism of action compared with other antidepressants.

This month’s Cochrane Corner review examines the evidence available for the use of vortioxetine as a first-line treatment for depression in adults.

This commentary puts the Cochrane review’s findings into their clinical context and revises them in view of earlier and later studies

Citations

Riccardo de Giorgi. Vortioxetine for depression: the evidence for its current use in the UK: COMMENTARY ON… COCHRANE CORNER. BJPsych Advances Vol 25. 1 2019 p3-6.

DOI: https://doi.org/10.1192/bja.2018.62

URI: https://www.oxfordhealth.nhs.uk/orka/title/vortioxetine-for-depression-the-evidence-for-its-current-use-in-the-uk-commentary-on-cochrane-corner/